Mature B-Cell Non-Hodgkin Lymphoma — Trials

Mature B-Cell Non-Hodgkin Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

2,506 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 792
Recruiting: 401
Ph III recruiting: 40
Growth YoY: +11.1%
Industry share: 24%
Top sponsor: National Cancer Institute (NCI)
Termination share: 36.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (393)

clinicaltrialsPublishedShowing 1–50 of 768 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03223610	Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma	recruiting	Phase 1 / Phase 2	155	National Cancer Institute (NCI)NIH	1	Sep 28, 2026	clinicaltrials
NCT05006716	A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies(CaDAnCe-101)	recruiting	Phase 1 / Phase 2	645	BeOne MedicinesINDUSTRY	16	Sep 28, 2026